Literature DB >> 15775070

[Pharmacological actions and pharmacokinetics of bisphosphonates].

Sadaaki Takeyama1, Hisashi Shinoda.   

Abstract

Bisphosphonates are potent inhibitors of osteoclastic bone resorption and have been used for the treatment of various metabolic bone diseases such as osteoporosis and hypercalcemia of malignancy. However, the pharmacological action, the mechanism of action, and even side effects vary depending on the chemical structure of the side chain attached to the carbon atom of P-C-P bond. This review discussed about the pharmacological characteristics and possible application of different classes of bisphosphonates with different side chains.

Entities:  

Year:  2003        PMID: 15775070     DOI: CliCa0302115121

Source DB:  PubMed          Journal:  Clin Calcium        ISSN: 0917-5857


  4 in total

Review 1.  Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials.

Authors:  T Lin; S-G Yan; X-Z Cai; Z-M Ying
Journal:  Osteoporos Int       Date:  2011-09-20       Impact factor: 4.507

Review 2.  Diffuse ocular and orbital inflammation after zoledronate infusion-case report and review of the literature.

Authors:  Obi C Umunakwe; David Herren; Stephen J Kim; Sahar Kohanim
Journal:  Digit J Ophthalmol       Date:  2017-12-28

3.  Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.

Authors:  Nicla La Verde; Claudia Bareggi; Marina Garassino; Karen Borgonovo; Paola Sburlati; Donata Pedretti; Celso Bianchi; Silvia Perrone; Dorian Mihali; Stefano Cobelli; Cristina Mantica; Aurora Rizzo; Gabriella Farina
Journal:  Support Care Cancer       Date:  2008-07-29       Impact factor: 3.603

Review 4.  Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials.

Authors:  Tiao Lin; Shi-Gui Yan; Xun-Zi Cai; Zhi-Min Ying; Fu-Zhen Yuan; Xi Zuo
Journal:  Int J Endocrinol       Date:  2014-01-05       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.